Stock Traders Purchase Large Volume of Call Options on Genmab A/S (NASDAQ:GMAB)

Key Points

• Unusual options activity: Traders purchased 12,591 Genmab call options, roughly 403% above the average volume of 2,505 contracts, signaling heightened bullish interest.
• Positive Wall Street sentiment: JPMorgan upgraded Genmab to “overweight,” while analysts maintain a consensus “Moderate Buy” rating with an average price target of $43.39.
• Clinical catalysts remain central: Promising petosemtamab results in head-and-neck and colorectal cancers support ongoing Phase 3 programs, though confirmatory results and regulatory decisions remain key risks.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) saw some unusual options trading activity on Monday. Stock traders bought 12,591 call options on the stock. This represents an increase of approximately 403% compared to the average volume of 2,505 call options.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised shares of Genmab A/S from a "neutral" rating to an "overweight" rating in a report on Monday. Weiss Ratings raised shares of Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, September 1st. New Street Research set a $43.00 target price on shares of Genmab A/S in a research note on Wednesday, July 22nd. Morgan Stanley set a $42.00 target price on Genmab A/S in a research report on Tuesday, October 20th. Finally, HC Wainwright lifted their price target on Genmab A/S from $40.00 to $50.00 and gave the company a "buy" rating in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.39.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently bought and sold shares of GMAB. Integrated Wealth Concepts LLC purchased a new position in Genmab A/S during the second quarter worth approximately $31,000. V Square Quantitative Management LLC purchased a new stake in Genmab A/S in the 1st quarter valued at $34,000. Nykredit A S purchased a new stake in Genmab A/S in the 2nd quarter valued at $58,000. GAMMA Investing LLC grew its holdings in Genmab A/S by 16.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,978 shares of the company's stock valued at $109,000 after buying an additional 561 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Genmab A/S by 51.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,597 shares of the company's stock worth $123,000 after acquiring an additional 1,565 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported updated Phase 2 results for petosemtamab plus pembrolizumab in first-line recurrent or metastatic PD-L1-positive head and neck cancer. The combination produced a 28.2-month median overall survival, a 63% overall response rate, 9.0-month median progression-free survival and a 19% complete-response rate. Phase 3 data are expected later this year, creating a potentially important near-term catalyst. Genmab Phase 2 head and neck cancer results
• Positive Sentiment: Follow-up data for petosemtamab combined with chemotherapy in metastatic colorectal cancer showed objective response rates of 75% in first-line patients and 67% in second-line patients, including an 81% response rate among first-line patients with left-sided tumors. The results support ongoing global Phase 3 trials in colorectal cancer. Genmab colorectal cancer data
• Positive Sentiment: JPMorgan upgraded GMAB from “neutral” to “overweight,” adding Wall Street support to the positive clinical narrative. JPMorgan upgrade report
• Positive Sentiment: The Wall Street Journal reported that an experimental Genmab cancer drug reduced the risk of death and disease progression in a late-stage ovarian-cancer study, providing another favorable readout for the company’s oncology pipeline. Genmab ovarian cancer study results
• Neutral Sentiment: Although the petosemtamab results are promising, the key head and neck and colorectal programs remain dependent on confirmatory Phase 3 results, leaving clinical and regulatory risk ahead.

Genmab A/S Price Performance

NASDAQ GMAB traded up $0.96 on Monday, hitting $44.75. The company had a trading volume of 3,135,271 shares, compared to its average volume of 2,264,511. The company has a market capitalization of $27.92 billion, a PE ratio of 35.20, a PEG ratio of 2.01 and a beta of 0.81. The company's fifty day moving average price is $35.25 and its 200-day moving average price is $30.23. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $45.45.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.12 billion. As a group, analysts predict that Genmab A/S will post 1.22 earnings per share for the current year.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab's marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.